|  |
| --- |
| **CURRICULUM VITAE**June 2022 |
| Dirk F MooreAssociate Professor of Biostatistics and EpidemiologyRutgers School of Public HealthAssociate Member\*, Cancer Prevention and Control ProgramDepartment of Biostatistics, Room 5008Rutgers Cancer Institute of New Jersey120 Albany St.New Brunswick, NJ 08901Telephone: 732-235-7594Email: Dirk.Moore@rutgers.eduU.S. citizen |
| **Education** |
|  | Doctorate of Philosophy, BiostatisticsUniversity of Washington, Seattle Washington | 1985 |
| Dissertation topic: Method of Moments Estimation for Overdispersed Counts and Proportions Adviser: N. Breslow |
| Master of Philosophy, BiologyYale University, New Haven, Connecticut | 1978 |
| Bachelor of Arts, MathematicsCarleton College, Northfield, Minnesota | 1975 |
| **POSITIONS** |
|  | Postdoctoral Fellow, BiostatisticsHarvard School of Public Health | June 1985 -August 1988 |
| Assistant Professor, StatisticsTemple University | August 1988 – July 1994 |
| Associate Professor, StatisticsTemple University | August 1994 – June 2003 |
| Associate Professor, BiostatisticsRutgers School of Public Health (formerly named UMDNJ)Biostatistician, Rutgers Cancer Institute of New Jersey,Robert Wood Johnson School of Medicine | July 2003 - present |
| **ADJUNCT AND VISITING POSITIONS** |
|  | Visiting Research ScientistRadiation Effects Research FoundationHiroshima, Japan | January 1982 – July 1983 |
| Adjunct Associate Member, BiostatisticsFox Chase Cancer Center, Philadelphia, PA | June 1990 – March 1995 |
| Guest Researcher, Biostatistics BranchDivision of Cancer Epidemiology and GeneticsNational Cancer Institute, Rockville, MD | January 1998 – June 1998 |
| Consultant, BiostatisticsFox Chase Cancer Center, Philadelphia, PA | July 2000 – July 2003 |
| **SERVICE** |
|  | Rutgers School of Public Health Doctoral Committee | January 2004 – present |
| Ad Hoc Doctoral Support Committee, School of Public Health | March 2004 – July 2006 |
| Doctoral Program Coordinator for Biostatistics | July 2005 – July 2017 |
| Human Research Oversight Committee, Cancer Institute of New Jersey | September 2003 – present |
| Scientific Review Board, Cancer Institute of New Jersey | September 2004 – present |
| Member, Rutgers School of Public Health Academic Affairs Committee | September 2008 – present |
| Member Appointments and Promotions Committee, Rutgers School of Public Health | August 2012 – September 2017 |
| Member, Institutional Review Board, Rutgers Biomedical and Health Sciences | August 2012 - present |
| President, Philadelphia Chapter, American Statistical Association | July 1992 – June 1993 |
| Secretary, Princeton-Trenton Chapter, American Statistical Association | July 2004 – July 2007 |
|  | President, New Jersey Chapter, American Statistical Association Served as judge for statistical presentation at the New Jersey Regional Science Fair (high school), March 2011 Coordinated Spring Symposium 2011, “Bayesian and Frequentist Adaptive Designs in Clinical Trials”, held at RW Johnson Medical School auditorium in Piscataway, June 3, 2011 Coordinated Spring Symposium 2012, “Causal Inference in Clinical Trials, Epidemiology, and Social Science” June 8, 2012. | January 2011 – December 2013 |
|  | Member, Four NIEHS national grant review panels(NIEHS center, training, and superfund grant review panels) | September 2008 – August 2010 |
|   | Co-chair, Human Research Oversight Committee, Rutgers Cancer Institute of New Jersey | July 2014 – present |
|  Member, Human Research Executive Committee, Rutgers October 2014 - Cancer Institute of New Jersey present**TEACHING RESPONSIBILITIES**Instructor for core course in biostatistics for the School of Public Health and for other graduate courses, including “Applied Survival Data Analysis”, offered by the Department of Biostatistics**GRANT SUPPORT** |
|  |  |  |
|  | “A survey of current evaluation and treatment of gout” $12,500. N. Schlesinger, Rheumatology, RW Johnson Medicine (via Takeda Pharmaceuticals). Included 6 months biostat student support | July 2005 – June 2006 |
|  | “Acute gout in the emergency room” $6000. N Schlesinger, Rheumatology (via Novartis). Six months of biostat student support | July 2012 – Dec 2012 |
|  | CA-72720-04 (PI: R DiPaola) 23% effortNIH/NCI 00 Cancer Center Support Grant Shared Resource | March 2005 – present |
|  | RO1 CA116399-02 (PI: Grace Lu-Yao). 25% effort NIH / NCI “Evaluation of Palliative Prostate Cancer Among Elderly Men”  | August 2006 – December 2012 |
|  | 5R01C1CA145722 (PI: Grace Lu-Yao) 10% effort NIH / NCI“Evaluate long term prognosis of localized prostate cancer following initial radiation therapy” | September 2009 – September 2011 |
|  | P30 ES05022 (PI: Helmut Zarbl) 17% effortNIEHS (National Institute for Environmental and Health Sciences) Role: Biostatistician of the Biostatistics Facility Core | April 2002 – April 2012 |
|  | NIH / NIDDK “Lysosomal enzymes and associated genetic diseases” 5% effort (PI: P Lobel) | July 2008 – July 2020 |
|  | NIH / NIDDK "Novel lysosomal enzyme deficient inBatten disease" 5% effort (PI: P Lobel) | October 2009 – July 2020 |
|  | NIH / NINDS (PI: Peter Lobel and Hong Li)“Rutgers Mass Spectrometry Center for Integrative Neuroscience Research” NIH P-30 grant no 2P30NS046593-12Rutgers Mass Spectrometry Center for Integrative Neuroscience Research$2,544,000 Start July 1, 2015. Funded at 20% salary. | June 2015 – July 2020 |
| **PEER-REVIewEd Publications** |
| 1. Breslow, N.E. and **Moore, D.F.** (1985) Discussion (pp875-877) of P. Diaconis and B. Efron (1985) Testing for independence in a two-way table: new interpretations of the chi-square statistic. *Annals of Statistics* 13:845-874.
2. **Moore, D.F.** (1986) Asymptotic properties of moment estimators for overdispersed counts and proportions. *Biometrika* 73:583-588.
3. **Moore, D.F.** (1987) Modeling the extraneous variance in the presence of extra-binomial variation. *Applied Statistics* 36:8-14.
4. Spiers, A.S.D., **Moore, D.F.**, Cassileth, P.A., Harrington, D.P., Cummings, F.J., Neiman, R., Bennett, J.M., and O’Connell, M.J. (1987) Remissions in hairy cell leukemia with pentostatin (2’-deoxycoformycin). *New England J. Medicine* 316:825-830.
5. Bennett, J.M., Raphael, B., **Moore, D.**, Silber, R., Oken, M.M., Rubin, P. (1987) Comparison of chlorambucil and prednisone vs. cytoxan, vincristine, prednisone for the therapy of active chronic lymphocytic leukemia: A long term follow-up of two ECOG studies. In: *Chronic Lymphocytic Leukemia: Recent Progress and Future Directions* pp317-327.
6. Auger, I., Thomas, P., De Gruttola, V., Morse, D., **Moore, D.**, Williams, R., Truman, B., and Lawrence, C.E. (1988) Incubation periods for paediatric AIDS patients *Nature* 336: 575-577.
7. Lefkopoulou, M., **Moore, D.F.**, and Ryan, L.. (1989) The analysis of multiple discrete outcomes: Application to rodent teratology experiments. *J. Amer. Statis. Assoc.* 84:810-815.
8. **Moore, D.F.** and Tsiatis, A.. (1991) Robust estimation of the variance for moment methods for extra-binomial and extra-Poisson variation. *Biometrics* 47:383-401.
9. Friedland, L., Joffe, M., Wiley II, J.F., Schapire, A., and **Moore, D.F.** (1992) Effect of educational intervention on adherence with glove use in a pediatric emergency department. *Amer. J. of Diseases of Children* 146:1355-1358.
10. Finkelstein, D.M., **Moore, D.F.**, and D. A. Schoenfeld. (1993) A proportional hazards model for truncated AIDS data. *Biometrics* 49:731-740.
11. Szarka, C.E., Pfeiffer, G.R., Hum, S.T., Everley, L.C., Balshem, A.M., **Moore, D.F.**, Litwin, S., Goosenberg, E.B., Frucht, H., Engstrom, P.F., and Clapper, M.L. (1995) Glutathione S-Transferase Activity and Gluatathione S-Transferase *m* Expression in Individuals at Increased Risk for colorectal Cancer. *Cancer Research* 55:2789-2793.
12. Sakkas, L., **Moore, D.F.**, and Akritidis, N.C. (1995) Cancer in families with systemic sclerosis. *American Journal of Medical Sciences* 310:223-225.
13. Hanlon, A.L., **Moore, D.F.**, Hanks, G. (1998) Modeling postradiation prostate specific antigen level kinetics. *Cancer* 83: 130-134.
14. Wiernik, P.H., **Moore, D.F.**, et al (1998) Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine, prednisone for patients with diffuse histologic subtypes of non-Hodgkin’s lymphoma. *Leuk Lymphoma* 30: 601-607.
15. Ross, E.A. and **Moore, D.F.** (1999) Modeling clustered, discrete or grouped-time survival data with covariates. *Biometrics* 55: 813-819.
16. **Moore, D.F.**, Chatterjee, N., Pee, D., and Gail, M.H. (2001) Pseudo-likelihood estimates of the cumulative risk of an autosomal dominant disease gene from a kin-cohort study. *Genetic Epidemiology* 20: 210-227.
17. **Moore, D.F.**, C.K. Park, and W. Smith (2001) Exploring extra-binomial variation in teratology data using continuous mixtures. *Biometrics* 57: 490-494.
18. **Moore, D.F.,** (2002) Quasi-likelihood. Entry in *The Encyclopedia of Environmetrics*.
19. **Moore, D.F.** (2002) Survival Analysis. Entry in *The Encyclopedia of Biopharmaceutical Statistics*.
20. Watkins-Bruner, D., **Moore, D.**, Parlanti, A., Dorgan, J., Engstrom, P. (2003) Relative risk of prostate cancer for men with affected relatives: Systematic review and meta-analysis. *International Journal of Cancer,* 107(5), 797-803.
21. **Moore, D.F.** and Smith, W (2004) Applications of the beta-binomial distribution in animal teratology experiments. Chapter in *Handbook of the Beta Distribution. (Statistics Textbooks and Monographs No. 174)*. A.K. Gupta & S. Nadarajah, editors. Marcel-Dekker pp 529–534.
22. Bass, S.B., Ruzek, S.B., Fleisher, L., McKeown-Conn, N., Gordon, T.F., **Moore, D**. (2006) Relationship of internet health information use with patient behavior and self-efficacy: Experiences of newly diagnosed cancer patients who contact the National Cancer Institute’s Cancer Information Service. *Journal of Health Communication* 11(2), 219-236.
23. Lu-Yao, G, **Moore, D.F**., Oleynick, J., DiPaola, R. Yao, S.-L. (2006) Utilization of hormonal therapy among men with metastatic prostate cancer. *Journal of Urology,* 176, 526-531.
24. Schlesinger, N., **Moore, D.F**., Sun, J.D., Schumacher, H.R. (2006) A survey of current evaluation and treatment of gout. *Journal of Rheumatology,* 33(10), 2050-2052.
25. **Moore, D.F.** (2006) Relative risk. Entry in *Encyclopedia of Measurement and Statistics* (Sage Press) edited by N.J. Salkind, Vol 3, pp832-833.
26. Lu-Yao, G., **Moore, D.F**., Oleynick, J.U., DiPaola, R.S., and Yao, S.-L. (2007) Population-based study of hormonal therapy and survival in men with metastatic prostate cancer. *Journal of Urology* 177, 535-539.
27. Kushi, L, Bandera, EV, **Moore, D**., McCullough, M, Freudenheim, JL, Jacobs, DR, Rastogi, T Systematic Literature Review: Diet and endometrial cancer risk. In: *Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective. World Cancer Research Foundation.* 2007.
28. Wu, Y, **Moore, DF**, and Shih WJ (2007) Estimating survival curve with unlinked entry and failure times. *Statistics in Medicine* 26(19), 3624-3638.
29. Bandera, EV, Kushi LH, **Moore DF**, Gifkins DM, McCullough ML (2007). Fruits and vegetables and endometrial cancer risk: a systematic literature review and meta-analysis. *Nutr Cancer* 58:6-21.
30. Bandera EV, Kushi LH, **Moore DF**, Gifkins DM, McCullough ML. (2007) Dietary lipids and endometrial cancer: the current epidemiologic evidence. *Cancer Causes Control* 18:687-703.
31. Bandera EV, Kushi LH, **Moore DF**, Gifkins DM, McCullough ML. (2007) Consumption of animal foods and endometrial cancer risk: A systematic literature review and meta-analysis. *Cancer Causes Control* 18:967-988.
32. Bandera EV, Kushi LH, **Moore DF**, Gifkins DM, McCullough ML. (2008) Association between dietary fiber and endometrial cancer: A dose-response meta-analysis. *The American Journal of Clinical Nutrition* 86:1730-1737.
33. Wu, Y, Shih WJ, **Moore, DF**. (2008) Elicitation of a beta prior for Bayesian inference in clinical trials. *Biometrical Journal* 50: 212–223.
34. Qian M, Sleat DE, Zheng H, **Moore D**, Lobel P. (2008) Proteomic analysis of serum from mutant mice reveals lysosomal proteins selectively transported by each of the two mannose 6-phosphate receptors. *Molecular and Cellular Proteomics* 7:58-70.
35. Thompson RL, Bandera EV, Burley VJ, Cade JE, Forman D, Freudenheim JL Greenwood D, Jacobs Jr DR, Kalliecharan RV, Kushi LH, McCullough ML, Miles LM, **Moore DF**, Moreton JA, Rastogi T, Wiseman MJ. (2008) Reproducibility of systematic literature reviews on food, nutrition, physical activity and endometrial cancer. *Public Health Nutrition* 2008; 11, 1006-1014
36. Bandera EV, Kushi LH, **Moore DF**, McCullough ML. (2008) Vitamin D and calcium intake in relation to risk of endometrial cancer: a systematic review of the literature. *Preventive Medicine* 46, 298-302.
37. Sleat, D, Della Valle, MC, Zheng, H, **Moore D**, Lobel, P. (2008) The mannose 6-phosphate glycoprotein proteome. *Journal of Proteome Research* 7, 3010-3021.
38. Lu-Yao G, Albertsen PC, **Moore DF**, Shih WJ, Lin, Y, DiPaola RS, Yao SL. (2008) Survival following primary androgen deprivation therapy among men with localized prostate cancer. *J. American Medical Association* 300, 173-181. doi:10.1001/jama.300.2.173
39. Ananth CV, Peltier MR, **Moore D**, Kinzler WL, Leclerc D, Rozen RR, for the New Jersey-Placental Abruption Study Investigators. Reduced folate carrier (80A🡪G) polymorphism, plasma folate and risk of placental abruption. *Human Genetics* 2008;124:137-145.

doi:10.1007/s00439-008-0531-71. Schaar, D, Medina, DJ, **Moore DF**, Strair, RK, and Ting, Y. miR-320 inhibits cell proliferation by repressing transferrin receptor 1 (CD71). *Experimental Hematology* 2009; 37, 245-255. http://dx.doi.org/10.1016/j.exphem.2008.10.002
2. Bandera EV, Kushi LH, **Moore DF**, McCullough ML. Antioxidant vitamins and the risk of endometrial cancer: a dose-response meta-analysis. *Cancer Causes and Control* 2009; 20:699–711. doi:10.1007/s10552-008-9283-x

1. Liu J, Chen L, Zhao H, **Moore DF**, Lin Y, Shih, WJ. On calculating the probability of a set of orthologous sequences. *Computational Biology and Chemistry: Advances and Applications* 2009; 2, 37-48. (2009) PMCID: PMC3169941
2. Deng, L and **Moore DF**. Composite likelihood modeling of neighboring site correlations of DNA sequence substitution rates. *Statistical Applications in Genetics and Molecular Biology.* (2009) Vol. 8, Iss. 1, Article 6. doi:[10.2202/1544-6115.1391](https://doi.org/10.2202/1544-6115.1391)
3. Budak-Alpdogan T, Chen B, Warrier A, Medina DJ, **Moore DF**, and Bertino JR. Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma. *Clin Cancer Res* 2009; 1232-1240. doi:10.1158/1078-0432.CCR-08-0810
4. Sleat, DE, Ding, L, Wang, S, Zhao, C, Want, Y, Xin, W, Zheng, H, **Moore, DF**, Sims, KB, Lobel, P. Mass spectrometry-based protein profiling to determine the cause of lysosomal storage diseases of unknown etiology. *Molecular and Cellular Proteomics* (2009) 8, 1708 – 1718. doi:10.1074/ mcp.M900122-MCP200
5. Lu-Yao, GL, Albertsen, PC, **Moore, DF**, Shih, WJ, Lin, Y, DiPaola, RS, Barry, MJ, Zietman, A, O’Leary, M, Walker-Corkery, E, and Yao, S-L Outcomes of localized prostate cancer following conservative management. *J. American Medical Association,* (2009) 302, 1202 – 1209. doi:10.1001/jama.2009.1348
6. Qian, H., N. Fiedler, **D. F. Moore,** and C. P. Weisel. 2010. Occupational Exposure to Organic Solvents during Bridge Painting. *Annals of Occupational Hygiene*, 54, 417 - 426. doi: 10.1093/annhyg/meq021
7. Jabbour, SK, Tuli, R, Patel, S, Chandra, R, Chen, C, **Moore, D**, Herman, J (2010) Intensity modulated radiation therapy (IMRT) for rectal cancer can reduce acute toxicities of chemoradiation. International Journal of Radiation Onclogy Biology Physics 78 (3), S324. http://dx.doi.org/10.1155/2012/891067
8. Marshall, H., M Bhaumik, H. Aviv, **D. Moore,** M. Yao, J. Dutta, H. Rahim, M. Gounder, S. Ganesan, A. Saleem, E. Rubin (2010) Deficiency of the dual ubiquitin/SUMO ligase topors results in genetic instability and increased rate of malignancy in mice. BMC Mol. biol. 11, 31. (14 pages).

doi:10.1186/1471-2199-11-311. Kongara, S., O. Kravchuk, I. Teplova, F. Lozy, J. Schulte, **D. Moore**, N. Barnard, C. A. Neumann, E. White, and V. Karantza. 2010. Autophagy Regulates Keratin 8 Homeostasis in Mammary Epithelial Cells and in Breast Tumors. *Molecular Cancer Research* 8, no. 6 (6): 873-884. doi:10.1158/1541-7786
2. Albertsen, PC, **Moore, DF**, Shih, WJ, Yong Lin, Li, H, and Lu-Yao, GL (2011) Impact of co-morbidity on survival among men with localized prostate cancer. *Journal of Clinical Oncology*, 29, 1335-1341 (2011) doi:10.1200/jco.2010.31.2330
3. Della Valle, MC, Sleat, D, Zheng H, **Moore, DF**, Jadot M, Lobel, P. Classification of subcellular location by comparative proteomic analysis of native and density-shifted lysosomes*. Molecular and Cellular Proteomics*, 10, 2011. doi:10.1074/mcp.M110.006403
4. Roberts CB, Albertsen PC, Shao YH, **Moore DF**, Mehta AR, Stein MN, Lu-Yao GL. Patterns and correlates of prostate cancer treatment in older men. Am J Med 24, 235-243 (2011). doi:10.1016/j.amjmed.2010.10.016
5. Roberts, CB, Jang, TL, Shao, Y-H, Kabadi, S, **Moore, DF**, Lu-Yao, GL (2011) Treatment profile and complications associated with cryotherapy for localized prostate cancer: A population-based study. *Prostate Cancer and Prostatic Diseases* 14, 313-319. doi:10.1038/pcan.2011.17
6. Kim, S, Shen, S, **Moore, DF**, Shih, WJ, Lin, Y, Li, H, Dolan, M, Shao, Y-H, Lu-Yao, (2011) Late gastrointestinal toxicities following radiation therapy for prostate cancer. *European Urology* 60, 908-916. http://dx.doi.org/10.1016/j.eururo.2011.05.052
7. Jabbour, SK, Daroui, P, **Moore, D**, Licitra, E, Gabel, M, Aisner, J. A novel paradigm in the treatment of oligometastatic non-small cell lung cancer. *Journal of Thoracic Disease*, (2011) 3, 4–9.
8. Neboori, H, Haffty BG, S, Wu, H, Yang, Q, Aly A, Goyal, S, Schiff, D, Moran, MS, Golhar, R, Chen, C, **Moore, D**, Ganesan (2012) Low p53 binding protein 1 (53BP1) expression is associated with increased local recurrence in breast cancer patients. *International Journal of Radiation Oncology, Physics* 2012 Apr 18. doi:10.1016/j.ijrobp.2012.01.089
9. Dong, G, Shih, WJ**, Moore, D**, Quan, H, Marcella, S (2012) A Bayesian-frequentist two-stage single-arm phase II clinical trial design. *Statistics in Medicine* 31, 2027-2150. DOI: 10.1002/sim.5330
10. Budak-Alpdogan T, Jeganathan G, Lee K-C, Mrowiec ZR, Todd D, **Moore D**, Bertino JR, Strair R (2012) Irradiated allogeneic cells enhance umbilical cord blood stem cell engraftment in immunodeficient mice. *Bone Marrow Transplantation* 47, 1569–1576. . doi: 10.1038/bmt.2012.69
11. Lu-Yao GL, Albertsen PC, Li H, **Moore DF**, Shih W, Lin Y, DiPaola RS, Yao S-L (2012) Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer? *European Eurology* <http://dx.doi.org/10.1016/j.eururo.2012.05.003>
12. Jabbour, SK, Patel, S, Herman, JM, Wild A, Nagda SN, Altoos T, Tunceroglu A, Azad N, Gearheart S, Moss RA, Poplin E, Levinson LL, Chandra RA, **Moore DF**, Chen C, Haffty BG, Tuli R (2012) Intensity-modulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits. *International Journal of Surgical Oncology.* doi: 10.1155/2012/891067.
13. Rebecca A. Moss, **Dirk Moore**, Mary Mulcahy, Kenneth Nahum, Biren Saraiya, Simantini Eddy, Martin Kleber, Elizabeth Poplin; “A Multi-Institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer”; *Gastrointestinal Cancer Research*, Volume 5(3):77-83, 2012. http://dx.doi.org/10.1016/j.eururo.2013.05.023
14. Sleat D, Wiseman J, Sohar I, El-Banna M, Zheng H, **Moore D**, Lobel P (2012) Proteomic analysis of mouse models of Niemann-Pick C disease reveals alterations in the steady-state levels of lysosomal proteins within the brain. *Proteomics* 12, 3499-3509. doi:10.1002/pmic.201200205
15. Nelson, C., S. Kim, S. Shen, Y. Shao, T. Mayer, **D. Moore**, and G. Lu-Yao. "Certificate of Need (CON) Status and its Impact on Overtreatment of Low-risk Prostate Cancer in the Elderly." *International Journal of Radiation Oncology\* Biology\* Physics* 84, no. 3 (2012): S123-S124.
16. Kim S, **Moore DF**, Shih W, Lin Y, Li H, Shao YH, Shen S, Lu-Yao GL (2013) Severe genitourinary toxicity following radiation therapy for prostate cancer-How long does it last? *Journal of Urology* 189, 116-121. doi:10.1016/j.juro.2012.08.091
17. Eng OS, Goswami J, **Moore D**, Chen C, Gannon C, August D, Carpizo DR (2013) Intraoperative fluid administration rate correlates with perioperative outcomes in patients undergoing pancreaticduodenectomy. *Annals of Surgical Oncology* 20, S136.
18. YH Shao, **DF Moore,** W Shih, Y Lin, TL Jang, GL Lu‐Yao (2013) Fractures after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU International 111, 745-752. DOI: 10.1111/j.1464-410X.2012.11758.x
19. [Sleat DE](http://www.ncbi.nlm.nih.gov/pubmed?term=Sleat%20DE%5BAuthor%5D&cauthor=true&cauthor_uid=23478313), [Sun P](http://www.ncbi.nlm.nih.gov/pubmed?term=Sun%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23478313), [Wiseman JA](http://www.ncbi.nlm.nih.gov/pubmed?term=Wiseman%20JA%5BAuthor%5D&cauthor=true&cauthor_uid=23478313), [Huang L](http://www.ncbi.nlm.nih.gov/pubmed?term=Huang%20L%5BAuthor%5D&cauthor=true&cauthor_uid=23478313), [El-Banna M](http://www.ncbi.nlm.nih.gov/pubmed?term=El-Banna%20M%5BAuthor%5D&cauthor=true&cauthor_uid=23478313), [Zheng H](http://www.ncbi.nlm.nih.gov/pubmed?term=Zheng%20H%5BAuthor%5D&cauthor=true&cauthor_uid=23478313), [**Moore DF**](http://www.ncbi.nlm.nih.gov/pubmed?term=Moore%20DF%5BAuthor%5D&cauthor=true&cauthor_uid=23478313), [Lobel P](http://www.ncbi.nlm.nih.gov/pubmed?term=Lobel%20P%5BAuthor%5D&cauthor=true&cauthor_uid=23478313). (2013) Extending the mannose-6 phosphate glycoproteome by high resolution/accuracy mass spectrometry analysis of control and acid phosphatase 5-deficient mice.*Molecular Cell Proteomics* PMID: 23478313 doi: [10.1074/mcp.M112.026179](http://dx.doi.org/10.1074/mcp.M112.026179)
20. Mehta MS, Dolfi SC, Bronfenbrener R, Bilal E, Chen C, **Moore D**, Lin Y, Rahim H, Aisner S, Kersellius RD, The J, Chen S, Toppmeyer DL, Hirshfield KM. (2013) Metabotropic Glutamate Receptor 1 Expression and Its Polymorphic Variants Associate with Breast Cancer Phenotypes. PLoS ONE 8(7): e69851. doi:10.1371/journal.pone.0069851 PMCID: [PMC3724883](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724883/)
21. Oliver S Eng, Julie Goswami, **Dirk Moore**, Chunxia Chen, Jennifer Brumbaugh, Christopher J Gannon, David A August, Darren R Carpizo (2013) Safety and efficacy of LigaSure usage in pancreaticoduodenectomy. HPB (International Hepato-Pancreato-Biliary Association).DOI: 10.1111/hpb.12116*.* 10, 747-752.
22. Carpizo DR, Gensure RH, Yu X, Gendel VM, Greene SJ, **Moore DF**, Jabbour SK, Nosher JL (2014) Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres. J Vascular Interventional Radiology 25, 297-306.
23. Shao YHJ, Kim S, Moore DF, Shih W, Lin Y, Stein M, Kim IY, Lu-Yao GL (2014) Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based propensity score-matched analysis. *European Urology* 65, 693-700. DOI: <http://dx.doi.org/10.1016/j.eururo.2013.05.023>
24. Grace L Lu-Yao, Peter C Albertsen, **Dirk F Moore,** Weichung Shih, Yong Lin, Robert S DiPaola, Siu-Long Yao Fifteen-Year Survival Outcomes Following Primary Androgen-Deprivation Therapy for Localized Prostate Cancer. *JAMA Internal Medicine* 174 (9) 1460-1467 (2014)
25. Irina V Tereshchenko, Hua Zhong, Marina A Chekmareva, Noriko Dane-Goldsmith, Urmila Santanam, Whitney Petrosky, Mark N Stein, Shridar Ganesan, Eric A Singer, **Dirk Moore**, Jay A Tischfield, Robert S DiPaola (2014) ERG and CHD1 heterogeneity in prostate cancer: Use of confocal microscopy in assessment of microscopic foci. *The Prostate* 74 (15) 1551-1559.
26. Eng OS, Tsang AT, **Moore D**, Chen C, Narayanan S, Gannon CJ, August DA Carpizo DR Melstrom LG. Outcomes of microwave ablation for colorectal cancer liver metastases: A single center experience. Journal of Surgical Oncology (2014) DOI: 10.1002/jso.23849
27. Arlow RL, **Moore, DF**, Chen C, Langenfeld J, August DA Outcome-volume relationships and transhiatal esophagectomy: minimizing failure to rescue. Annals of Surgical Innovataion and Research (2014) 8:9 (7p). http://www.asir-journal.com/content/8/1/9
28. Lu-Yao GL, Albertsen PC, **Moore DF**, DiPaola RS, Yao SL. Fifteen-year outcomes following conservative management among men aged 65 years or older with localized prostate cancer. *European Urology* (2015) 68, 805-811
29. Schlesinger N, Radvanski DC, Young TC, McCoy JV, Eisenstein R, and **Moore DF**. Diagnosis and treatment of acute gout at a university hospital emergency department. *The Open Rheumatology Journal* (2015) 9, 21-26.
30. Lu-Yao GL, Kim S, **Moore DF** Shih WJ, Lin Y, DiPaola RS, Shen S, Zietman A, Yao SL. Primary radiotherapy vs. conservative management for localized prostate cancer - a population-based study. *Prostate Cancer and Prostatic Diseases*, on-line June 23, 2015. doi: 10.1038/pcan.2015.30
31. Eng OS, Arlow RL, **Moore D**, Chen C, Langenfeld JE, August DA, Carpizo DR. Fluid administration and morbidity in transhiatal esophagectomy. *Journal of Surgical Research*, July 16, 2015. http://dx.doi.org/10.1016/j.jss.2015.07.021

 http://dx.doi.org/10.1016/j.jss.2015.07.0211. Kim S, Patel AN, Nelson C, Shen S, Mayer T, **Moore DF**, Lu-Yao GL (2016) Does certificate of need minimize intensity modulated radiation therapy use in patients with low risk prostate cancer? Urology Practice [doi:10.1016/j.urpr.2015.09.001](http://dx.doi.org/10.1016/j.urpr.2015.09.001)
2. He J, Albertsen P, **Moore D**, Rotter D, Demissie K, Lu-Yao G (2016) Validation of a contemporary five-tiered Gleason grade grouping using population-based data. Europearn Eurology 71, 760-763. http://dx.doi.org/10.1016/j.eururo.2016.11.031
3. Jadot M, Boonen M, Thirion J, Wang N, Xing J, Zhao C, Tannous A, Qian M, Zheng H, Everett JK, **Moore DF**, Sleat DE, Lobel P (2016) Accounting for protein subcellular localization: a compartmental map of the rat liver proteome.*Molecular and Cellular Proteomics* 16, 194-212. doi:10.1074/mcp.M116.064527 PMCID: PMC5294208
4. Wiseman JA, Meng Y, Nemtsova Y, Matteson PG, Milonig JH, **Moore DF,** Sleat DE, Lobel P (2017) Chronic enzyme replacement therapy to the brain in a mouse model of late-infantile neuronal ceroid lipofuscinosis has differential effects on phenotypes of disease. Molecular Therapy - Methods & Clinical Developmen 4, 204-212. http://dx.doi.org/10.1016/j.omtm.2017.01.004
5. Meng Y, Wiseman JA, Nemtsova Y, **Moore DF**, Guevarra J, Reuhl K, Banks WA, Daneman R, Sleat DE, Lobel P (2017) A basic ApoE-based peptide mediator to deliver proteins across the blood-brain barrier: Long-term efficacy, toxicity, and mechanism. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2017.03.037 PMCID: PMC5498811
6. Cercek A, Gendel V, Jabbour S, **Moore D**, Chen C, Nosher J, Capanu M, Chou J, Boucher T, Kemeny N, Carpizo D A comparison of yttrium-90 microsphere radioembolization to hepatic arterial infusional chemotherapy for patients with chemo-refractory hepatic colorectal metastases. *Current Treatment Options in Oncology* 18 (7) doi: 10.1007/s11864-017-0481-1
7. Khan AJ, Poppe MM, Goyal S, Kokeny KE, Kearney T, Kirstein L, Toppmeyer D, **Moore DF**, Chen C, Gaffney DK, Haffty BG (2017) Hypofractionated postmastectomy radiation therapy is safe and effective: First results from a prospective Phase II trial. *Journal of Clinical Oncology*

DOI: https://doi.org/10.1200/JCO.2016.70.7158 PMCID: PMC547617488. Sleat DE, Tannous A., Sohar I, Wiseman JA, Zheng H. Qian M., Zhao C., Xin W., Barone R., Sims K.B., Moore D.F., Lobel P. (2017) Proteomic analysis of brain and cerebrospinal fluid from the three major forms of neuronal ceroid lipofuscinosis reveals potential biomarkers. Journal of Proteome Research doi:10.1021/acs.jproteome.7b00460 PMCID: PMC586080789. Yu X, Kogan S, Chen Y, Tsang AT, Withers T, Lin H, Gilleran J, Buckley B, Moore D, Bertino J, Chan C, Kimball SD, Loh SN, Carpizo DR. Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics. Clin Cancer Res. 2018 SEP 15; 24(18):4505-4517. DOI: 10.1158/1078-0432.CCR-18-0822. 2018 Jun 18. PubMed PMID: 29914895; PMCID: PMC613904090. Jang TL, Patel N, Faiena I, Radadia D, **Moore DF**, Elsamra SE, Singer EA, Stein MN, Eastham JA, Scardion PT, Lin Y, Kim IY, Lu-Yao GL. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. *Cancer* (2018) DOI: 10.1002/cncr.3172691. Ferrari AC, Alumkal JJ, Stein MN, Taplin ME, Babb JS, Barnett ES, Gomez-Pinillos A, Xiaomei L, **Moore DF**, DiPaola RS, Beer TM. Epigenetic therapy with panobinostat combined with bicalutamide re-challenge in castration-resistant prostate cancer. *Clinical Cancer Research* (2018) DOI: 10.1158/1078-0432.CCR-18-1589.92. Yu Z, Kogan S, Chen Y, Tsang AT, Withers T, Lin Hongxia Gilleran J, Buckley B, **Moore D**, Bertino J, Chan C, Kimball SD, Loh SN, Carpizo DR (2018) Zinc metallochaperones reactivate mutant p53 using an on/off switch mechanism: A new paradigm in cancer therapeutics. *Clinical Cancer Research* DOI: 10.1158/1078-0432.CCR-18-082293. Khan AJ, Chen PY, Yashar C, Poppe MM, Li L, Yehia ZA, Vicini FA, **Moore D**, Dale R, Arthur D, Shah C, Haffty BG Kuske R. Three-fraction accelerated partial breast irradiation (APBI) delivered with brachyterapy applicators is feasible and safe: first results from the TRIUMPH-T trial (2019) *International Journal of Radiation Oncology Biology, Physics* https://doi.org/10.1016/j.ijrobp.2018.12.05094. Ali ND, Donohue K, Zandieh S, Chen C, **Moore D**, Poplin E, Shat MM, Nosher J, Gui B, Jabbour SK, Spencer K, Carpizo DR (2019) Conditional survival analysis of metastatic colorectal cancer patients living >- 24 months: A single institutional study. American Journal of Clinical Oncology, online. DOI: 10.1097/COC.0000000000000535. PMID: 3097337095. Na B, Yu X, Withers T, Gilleran J, Yao M, Foo TK, Chen C, **Moore D**, Lin Y, Kimball SD, Xia B, Ganesan S, Carpizo DR. Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation (2019). npj Breast Cancer 5 (14) 1-10 (2019)https://doi.org/10.1038/s41523-019-0110-196. Sleat D, Wiseman J, El-Banna M, Zheng H, Zhao C, Soherwardy A, **Moore D**, Lobel P. Analysis of brain and cerebrospinal fluid from mouse models of the three major forms of neuronal ceroid lipofuscinosis reveals changes in the lysosomal proteome. *Molecular and Cellular Proteomics* 18, 2244-2261 (2019) https://doi.org/10.1074/mcp.RA119.00158797. NeMoyer RE, Pantin E, Aisner J, Jongco R, Mellender S, Chiricolo A, **Moore DF**, Langenfeld J. Paravertebral nerve block with liposomal bupivacaine for pain control following video-assisted thoracoscopic surgery and thoracotomy. J Surgical Res 246, 19-25. 2020. https://doi.org/10.1016/j.jss.2019.07.09398. Gupta A, Khan A, Yegya-Raman N, Sayan M, Ahlawat S, Ohri N, Goyal S, **Moore D**, Eladoumikdachi F, Toppmeyer D, Haffty B. 5-year results of a prospective phase 2 trial evaluating 3-week hypofractionated whole breast radiation therapy inclusive of a sequential boost. *International Journal of Radiation Oncology Biology Physics* 105 (2) 264-274. 2019.https://doi.org/10.1016/j.ijrobp.2019.05.06399. Tannous A, Boonen M, Zheng H, Zhao C, Germain C, **Moore D**, Sleat D, Jadot M, Lobel P. Comparative Analysis of Quantitative Mass Spectrometric Methods for Subcellular Proteomics. *Journal of Proteome Research* 2020 https://dx.doi.org/10.1021/acs.jproteome.9b00862100. Poppe MM, Yehia ZA, Baker C, Goyal S, Tommmeyer D, Kirstein L, Chen C, **Moore DF**, Haffty BG, Khan AJ 5-year update of a multi institution prospective phase II hypofractionated post-mastectomy radiation therapy trial. International Journal of Radiation Oncology Biology Physics 2020. https://doi.org/10.1016/j.ijrobp.2020.03.020101. Yang Y, Karsli-Uzunbas G, Poillet-Perez L, Sawant A, Hu ZS, Zhao Y, **Moore D**, Hu W, and White E. Autophagy promotes mammalian survival by suppressing oxidative stress and p53. *Genes and Development* 34, 688-700. 2020. http://www.genesdev.org/cgi/doi/10.1101/gad.335570.119102. Shah MM, NeMoyer RE, Greco SH, Chen C, **Moore DF**, Grandhi MS, Langan RC, Kennedy TJ, Javidian P, Jabbour SK, Alexander HR, August DA, Carpizo DR. Subcategorizing T1 staging in pancreatic adenocarcinoma predicts survival in patients undergoing resection: An analysis of the National Cancer Database. *Journal of Pancreatic Cancer* 6, 64-72, 2020. https://doi.org/10.1089/pancan.2019.0017* 103. Krakora R, Shih W, Popi P, Gorshein E, Salaru G, **Moore D**, Chen C, David K, Bannerji R. Impact of insurance status on survival outcomes in adults with acute lymphoblastic leukemia (ALL): A single center experience. *Clinical Lymphoma Myeloma and Leukemia* 2020. https://doi.org/10.1016/j.clml.2020.06.010

104. Greco SH, August DA, Shah MM, Chen C, **Moore DF**, Masanam M, Turner AL, Jabbour SK, Javidian P, Grandhi MS, Kennedy J, Alexander HR, Carpizo DR, Langan RC (2021) Neoadjuvant therapy is associated with lower margin positivity rates after pancreaticoduodenectomy in T1 and T2 pancreatic head cancers: An analysis of the National Cancer Database. Surgery Open Science 3, pp22-28. https://doi.org/10.1016/j.sopen.2020.12.001105. Kangas-Dick AW, Greenbaum A, Gall V, Groisberg R, Mehnert J, Chen C, **Moore DF**, Berger AC, Koshenkov V. Evaluation of a gene expression profiling assay in primary cutaneous melanoma. Annals of Surgical Oncology 2021. https://doi.org/10.1245/s10434-020-09563-7106. Deek MP, Yegya-Raman N, Daroui P, Balasubramanian S, Malhotra J, **Moore D**, Patel M, Wang, S-J, Aisner J, Jabbour SK. (2021) Overexpression of excision repair cross-complementing 1 gene associates with higher risk of therapeutic failure after definitive chemoradiation for unresectable non-small cell lung cancer.  *Ann Palliat Med* 10(7): 7205 - 7213. https://dx.doi.org/10.21037/apm-21-182.107. Dansu DK, Liang J, Selcen I, Zheng H, **Moore DF**, Casaccia P. PRMT5 interacting partners and substrates in oligodendrocyte lineage cells. Frontiers in Cell Neuroscience 16, 820226. (2022). https://dx.doi.org/10.3389%2Ffncel.2022.820226108. Krupa K, Gribkova Y, Jain K, **Moore, D**, Chen C, Potdevin L, Kumar S, Eladoumikdachi F, Kowzun M. The use of intraoperative ultrasound during breast conserving surgery. Annals of Surgical Oncology, 2022, in press.109. Dansu DK, Liang J, Selcen I, Zehng H, **Moore DF**, Casaccia P. PRMT5 interacting partners and substrates in oligodendrocyte lineage cells. Frontiers in cellular neuroscience doi: [10.3389/fncel.2022.820226](https://doi.org/10.3389/fncel.2022.820226) PMCID: PMC8968030 PMID: [35370564](https://pubmed.ncbi.nlm.nih.gov/35370564)110. **Moore DF**, Sleat D, Lobel P. A method to estimate the distribution of proteins across multiple compartments using data from quantitative proteomics subcellular fractionation experiments. Journal of Proteome Research, 2022, 21, 6, 1371-1381 https://doi.org/10.1021/acs.jproteome.1c00781111. Gazivoda VP, Kangas-Dick AW, Greenbaum AA, Roshal J, Chen C, **Moore DF**, Langan RC, Kennedy TJ, Minerowicz C, Alexander HR. Expression of PD-L1 in patients with malignant peritoneal mesothelioma: A pilot study. *J Surgical Research* 277, 131-137 (2022) https://doi.org/10.1016/j.jss.2022.04.005My Bibliography (NIH)https://www.ncbi.nlm.nih.gov/myncbi/dirk.moore.1/bibliography/public/Google Scholar public profile: http://scholar.google.com/citations?user=PRJo41MAAAAJ**BOOK** 1. **Moore, D.F**. *Applied Survival Analysis Using R*. Springer, 2016. ISBN 978-3-319-31243-9. DOI 10.1007/978-3-319-31245-3. **BOOK REVIEWS**1.**. Moore, D.F.** (1991) Review of *Log-Linear Models* by R. Christensen. *J. Amer. Statist. Assoc.* 86: 1142-11432. Iglewicz, B., Heiberger, R., **Moore, D.**, and Tan, Y. (1995) Review of *Algorithms, routines, and S Functions for Robust Statistics* by A. Marazzi. Pacific Grove: Wadsworth & Brooks/Cole. *Technometrics* 37: 351-352.3. **Moore, D.F.** (1999) Review of *Log-Linear Models and Logistic Regression, 2nd ed.* by R. Christensen. *Journal of the American Statistical Association* 94: 348. 4. **Moore, D.F.** (2008) Review of *Applied Survival Analysis: Regression Modeling of Time-to-Event Data*, Second Edition, by DW Hosmer, S Lemeshow, and S May, New York: Wiley, 2008.  *J. Biopharmaceutical Statistics* 18, 1234-1236.5. **Moore DF**. Review of *SAS for Data Analysis: Intermediate Statistical Methods* by M. G. Marasinghe and W. J. Kennedy, New York: Springer. *J. Biopharmaceutical Statistics* (2009), in press. 6. **Moore DF**. Review of *Robust Methods in Biostatistics*, by S. Heritier, E. Cantoni, S. Copt, and M-P. Victoria-Feser, New York: Wiley, 2009, *J. Biopharmaceutical Statistics*, in press.7. **Moore DF**. Review of *SAS for Data Analysis: Intermediate Statistical Methods* by M. G. Marasinghe and W. J. Kennedy, New York: Springer. J. Biopharmaceutical Statistics 19, 935-937. doi:10.1080/105434009031055398. **Moore DF** (2011) Review of "Regression with Linear Predictors, by PK Andersen and L. T. Skovgaard, 2010". *Journal of Biopharmaceutical Statistics* 21(4), 20119. **Moore DF** (2015) Review of *Clinical Trial Biostatistics and Biopharmaceutical Applications* by W.R. Young and D-G. Chen. *Journal of Biopharmaceutical Statistics*25 (5), 1130-1131. doi: 10.1080/10543406.2015.1052293**INVITED PRESENTATIONS**1. “Robust estimation of the variance in the presence of extra-binomial variation" March, 1988, IMS meeting in Lexington, KY.2. “Modelling the mixing distribution in teratology data" May, 1993, Biopharmaceutical workshop, Muncie, IN.3. “Modelling the mixing distribution in teratology data" October, 1993, Third Merck-Temple Conference, Philadelphia, PA.4. “Power In Clinical Trials When an Important Prognostic Factor Cannot Be Observed” October, 1998 International Indian Association Conference, Hamilton, Ontario (with Bong Kim)5. “Random effects modeling of PSA levels in prostate cancer patients" October, 1998. Merck-Temple Conference, Philadelphia, PA (with Alexandra Hanlon)6. “Estimating the penetrance of a disease gene using a kin-cohort design" February, 1999. Fox Chase Cancer Center. (with Mitchell Gail and David Pee)7. “A pseudo-likelihood method for estimating the penetrance of a disease gene" April, 1999. University of Pennsylvania Department of Biostatistics and Epidemiology.8. “A pseudo-likelihood method for estimating the penetrance of a disease gene" February 2002. Yale University, Department of Biostatistics. 9. “What is the best way to manage prostate cancer? Causal inference using a geographical instrumental variable with the SEER/Medicare cohort.” April 2011, Dept. of Statistics, New Jersey Institute of Technology.10. “What is the best way to manage prostate cancer? Causal inference using a geographical instrumental variable with the SEER/Medicare cohort.” August 2012 Joint Statistical Meetings, San Diego, California11. “Propensity score and instrumental variable analysis methods for assessing causal effects of prostate cancer treatment using the SEER-Medicare database.” September 2013, Fox Chase Cancer Center, Philadelphia, PA**CONSULTING** Member, Data Safety Monitoring Committee, May 2011 – December 2016. Pfizer, Inc., New York, NY. **JOURNAL REVIEWING**Associate editor, Journal of Biopharmaceutical Statistics, March 2012 – May 2019.Multiple journals, including Journal of Clinical Oncology, Journal of Orthopedic Trauma, and others.**DOCTORAL DISSERTATION STUDENTS**Beth Barber (1993), Sue Ling Lai (1993), Choon-Keun Park (1995), Eric Ross (1996), Bong Kim (1997), Alexandra Hanlon (1998), Sherry Liu (1999), Qi Liu (1999), Robert Gagnon (2002), Ling Deng (2005), Yen-Hong Kuo (2010), Anjun Cao (2011), Qian Dong (2014), Carlin Brickner (2014) |